Policies

Statement of Practice: Flexibility Initiatives

IRBMED
Feb 3, 2020 2:45 pm

The University of Michigan's federalwide assurance with the Department of Health and Human Services (HHS) allows the IRB flexibility in its application of federal regulations to studies not federally funded or FDA-regulated.

Click here for PDF version.

  • STATEMENT OF PRACTICE

    The University of Michigan maintains a federalwide assurance (FWA00004969) with the Department of Health and Human Services (HHS) in which it pledges to comply with federal regulations for all federally supported research and also to follow the ethical principles of the Belmont Report (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research). This commitment allows the IRB flexibility in its application of federal regulations to studies that are not federally funded or FDA regulated. While continuing to apply the highest ethical standards for the protection of human subjects, this initiative will decrease the administrative burden on investigators and IRBMED Staff.

    The webpage HRPP Flexibility Initiatives also provides information current and historical flexibility initiatives and demonstration projects.

  • FLEXIBILITY INITIATIVE CRITERIA

    To qualify for any flexibility initiative, a study must pose no more than minimal risk to subjects and may not include any of the following:

    Studies intended to support proposals or future awards for federal funding usually should not use “flexibility initiatives,” out of an ‘abundance of caution.’ However, former federal funding is not a barrier to flexibility initiatives for an ongoing study.

    If a study also involves external site(s), the study team should check with outside contacts before agreeing to a U-M flexibility initiative. 

  • LIST OF FLEXIBILITY INITIATIVES

    Flexibility initiatives at IRBMED include, but are not necessarily limited to:

    • U-M Exemption 5: Research and demonstration projects sponsored by the State of Michigan
    • “No continuing review required” for ongoing studies (without triggering additional “2018 Requirements” under the Common Rule) that do not include genetic analysis
    • 24-month approval for Repository (REP) Applications that are not intended to facilitate genetic analysis

    Prior (retired) flexibility initiatives

Questions?

Contact us at [email protected] or 734-763-4768 / (Fax 734-763-1234)
2800 Plymouth Road, Building 520, Room 3214, Ann Arbor, MI 48109-2800

A list of IRBMED staff is available in the Personnel Directory, or view the list of Regulatory Teams.

Edited By: [email protected]
Last Updated: February 03, 2020 2:45PM